Lynozyfic

Lynozyfic is part of the Bispecific T-Cell Engagers class and treats Multiple Myeloma. Bispecific T-Cell Engagers treat certain types of prostate cancer. They work by engaging T-cells that are present in tumors but cannot recognize cancer cells and redirecting their activity toward the tumor. Lynozyfic is only available as a brand name drug.